TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

98 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

91 studies on the map

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) — Mayo Clinic in Arizona, ScottsdaleNeurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD — Emory Clinic, AtlantaPhase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments — Domino's Farms, Ann ArborVirtual tES Device Treatment for Parkinson's Disease Motor Symptoms — U LLC Headquarters, ClevelandClinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis — Johns Hopkins, BaltimoreA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. — Research Site, SurpriseA Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease — Banner Sun Health Research Institute, Sun CityA Study of Buntanetap in Participants With PD — University of Alabama at Birmingham, BirminghamAcute Equol Supplementation and Vascular Function in Women With and Without CKD — University of Colorado Anschutz Medical Campus, AuroraA Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD) — SouthCoast Research Center, Inc., MiamiSub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults — Harbor UCLA Medical Center, TorranceArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaA Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease — Research Site, DecaturRH Genotype Matched RBC Transfusions — Children's Hospital of Philadelphia, PhiladelphiaAnti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine — Brigham and Women's Hospital, BostonImaging Depression in Parkinson's Disease — Yale University, New HavenKetamine for Veterans With Parkinson's Disease — San Francisco VA Medical Center, San Francisco, CA, San FranciscoTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesEarly Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging) — Institute for Neurodegenerative Disorders, New HavenStudy to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD — Northwestern Memorial Hospital, ChicagoBone in CKD Alkali Response (BICARb Pilot Trial) — Albert Einstein College of Medicine, The BronxPsilocybin Therapy for Depression in Parkinson's Disease — University of California, San Francisco, San FranciscoCannabidiol in Sickle Cell Disease — Icahn School of Medicine at Mount Sinai, ManhattanEarly Screening and Treatment of Heart Complication in Sickle Cell Disease — Inova Schar Cancer, FairfaxTestosterone Treatment in Men With Chronic Kidney Disease — Saint Louis Univeristy, St LouisZinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial — UCSF Benioff Children's Hospital Oakland, OaklandAllo HSCT for High Risk Hemoglobinopathies — Masonic Cancer Center, MinneapolisA Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) — Mayo Clinic, PhoenixLow-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease — Quest Research Institute, Farmington HillsStudy to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD — New York University Langone Health, New YorkPyridostigmine for the Treatment of Constipation in Parkinson Disease — University of Vermont Medical Center, BurlingtonRehabilitation of Airway Protection in Parkinson's Disease — Purdue University, West LafayetteA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) — Memorial Sloan Kettering at Basking Ridge (Consent only), Basking RidgeA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamBreakthrough - T1DM and Chronic Kidney Disease — The University of Chicago, ChicagoPartial Stem Cell Transplant for Sickle Cell Disease From Matched Donors — National Institutes of Health Clinical Center, BethesdaThis Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease. — Cornell University Weill Medical College, New YorkTargeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin — University of Illinois Chicago, Sickle Cell Center, Chicago18F-mFBG Cardiac Uptake With Lewy Body Dementia — Houston Methodist Neurological Institute, HoustonSickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody — Children's National Hospital, Washington D.C.Tenapanor in Synucleinopathy-Related Constipation — Cedar Valley Digestive Health Center, WaterlooEvaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease — Institute for Neurodegenerative Disorders / XingImaging, LLC, New HavenA Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations — University of Arkansas for Medical Sciences, Little RockPatient Preference for Subcutaneous vs. Intravenous Immune Therapy — UPMC Hillman Cancer Center, PittsburghREgulatory T Cell Therapy to Achieve Immunosuppression REduction — Mayo Clinic in Arizona, PhoenixEquol and Vascular Function in Women With Chronic Kidney Disease — University of Colorado Anschutz Medical Campus, AuroraA Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia — R1 Therapeutics Clinical Trial Site, HuntsvilleA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease — University of Alabama Birmingham, BirminghamReduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders — Yale School of Medicine, New HavenGlucagon-Like Peptide-1 Receptor Agonist in ADPKD — University of Colorado - Anschutz Medical Campus, AurorarTMS to Improve Cognition in Parkinson's — Jesse Brown VA Medical Center, Chicago, IL, ChicagoAlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion — New York Medical College, ValhallaIntravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease — Children's National Hospital, Washington D.C.Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease — Purdue University, West LafayetteReducing Falls With Varenicline in Hypocholinergic Parkinson Disease — University of Michigan, Ann ArborSafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) — UAMS Medical Center, Little RockStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma — Stanford, Palo AltoSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis — Univ. of California, San Francisco Health Care, OaklandSafety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoA Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease — N America Res Inst - San Dimas, San DimasBiomarker-based Trial of NPC-1 for Alzheimer's Pathology — Massachusetts General Hospital, BostonRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease — Children's Hospital of Colorado, AuroraStudy to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease — Apogee Clinical Research, LLC, HuntsvilleA Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease — University of Kentucky Medical Center, LexingtonSafety and Efficacy of Empagliflozin in Hemodialysis — Brigham and Women's Hospital, BostonAlendronate for Osteonecrosis in Adults With Sickle Cell Disease — UC Davis Comprehensive Cancer Center, SacramentoMyeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease — University of California Los Angeles, Los AngelesNeurovascular Transduction During Exercise in Chronic Kidney Disease — Emory University Hospital Midtown, AtlantaStudy of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease — University of Illinois at Chicago, ChicagoImpact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile — Deepa Valvi, LexingtonThe University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy — UAB Advanced Imaging Facility, BirminghamRelationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET — St. Jude Children's Research Hospital, MemphisMinimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease — Children's National Health System, Washington D.C.T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias — Children's Hospital of Pittsburgh of UPMC, PittsburghUric Acid Lowering Trial in Youth Onset T2D — Children's Hospital Colorado, AuroraTocilizumab for Acute Chest Syndrome — University of Chicago, ChicagoCombination of Novel Therapies for CKD Comorbid Depression — Stony Brook University Medical Center, Stony BrookSafety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD — Clinical Trial Site, San FranciscoFerric Citrate and Chronic Kidney Disease in Children — University of California, Los Angeles, Los AngelesGene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesSodium Bicarbonate and Mitochondrial Energetics in Persons With CKD — University of California Davis Health, SacramentoSafety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant — University of Cincinnati, CincinnatiSit Less, Interact and Move More (SLIMM) 2 Study — Stanford University, StanfordIntranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease — Institute for Neuroimmune Medicine, DavieCognitive Remediation Intervention to Prepare for Transition of Care — University of Alabama at Birmingham, BirminghamA Phase 2/3 Study in Adult and Adolescent Participants With SCD — Smilow Cancer Hospital, New HavenCannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain — Mount Sinai Hospital, New YorkEffect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease — Northwestern University, ChicagoNAD Augmentation in Diabetes Kidney Disease — Brigham and Women's Hospital, BostonNAVIGATE Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities — Denver Health and Hospital Authority, DenverA Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease — Site-049, Birmingham